Last reviewed · How we verify

Isobaric bupivacaine 0.5%

Hospital Clínico Universitario de Valencia · FDA-approved active Small molecule

Isobaric bupivacaine blocks sodium channels in nerve fibers to produce local anesthesia with a specific gravity matching cerebrospinal fluid.

Isobaric bupivacaine blocks sodium channels in nerve fibers to produce local anesthesia with a specific gravity equal to cerebrospinal fluid, allowing it to remain at the injection site without migration. Used for Local and regional anesthesia for surgical procedures, Spinal anesthesia.

At a glance

Generic nameIsobaric bupivacaine 0.5%
Also known asB solution
SponsorHospital Clínico Universitario de Valencia
Drug classLocal anesthetic (amide class)
TargetVoltage-gated sodium channels
ModalitySmall molecule
Therapeutic areaAnesthesia
PhaseFDA-approved

Mechanism of action

Bupivacaine is a long-acting local anesthetic that inhibits sodium influx through voltage-gated sodium channels in nerve cell membranes, preventing depolarization and action potential propagation. The isobaric formulation has a specific gravity equal to cerebrospinal fluid, allowing it to remain at the injection site without significant migration during spinal anesthesia, providing more predictable and localized anesthetic effects.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: